Pra*ziquantel (also known as Biltricide) is a parasitic anthelmintic for humans and animals, specializing in the treatment of
tapeworms and flukes. It is particularly effective for Schistosoma japonicum, Chinese liver fluke, and Taenia gigantea.
Pra*ziquantel is a on the World Health Organization's Essential Standard List and one of the most important for basic public health in the world.
Pra*ziquantel belongs to the family of medicines called anthelmintics. Anthelmintics are used in the treatment of worm infections. Pra*ziquantel works by causing severe spasms and paralysis of the worms' muscles. Some kinds of worms are then passed in the stool.
Pra*ziquantel is an isoquinoline compound that is used to treat human schistosomiasis on a large scale. It is a safe, nontoxic drug that is given orally in a single dose of 40 mg/kg of body weight and is highly effective against all human schistosomes, with cure rates of 80% to 90%.
Function of Pra*ziquantel
(1) Pra*ziquantel has a particularly dramatic effect on patients with schistosomiasis.Studies of those
treated have shown that within six months of receiving a dose of pra*ziquantel,up to 90% of the damage
done to internal organs due to schistosomiasis infection can be reversed.
(2) Pra*ziquantel is an anthelmintic or anti-worm medication. Pra8ziquantel prevents newly hatched larvae
(worms) from growing or multiplying in your body.
(3) Pra*ziquantel is used to treat infections caused by Schistosoma worms,which enter the body through
skin that has come into contact with contaminated water.
(4) Pra*ziquantel is also used to treat infection with liver flukes,caused by a type of worm found in East
Asia.This worm enters the body while eating contaminated fish. Pra*ziquantel 99% powder Price bulk
pra*ziquantel powder
Parasitic diseases are major constraints in fish mariculture. The anthelmintic pra*ziquantel (PZQ) can effectively treat a range of flatworm parasites in a variety of fish species and has potential for broader application than its current use in the global aquaculture industry.
* The statements in this section have not been evaluated by the FDA or EFSA.
References
1.Boniatti J, Januskaite P, Fonseca LBD, Viçosa AL, Amendoeira FC, Tuleu C, Basit AW, Goyanes A, Ré MI.Pharmaceutics. 2021 Jul 21;13(8):1114. doi: 10.3390/pharmaceutics13081114.PMID: 34452075
2.Zanolla D, Perissutti B, Passerini N, Chierotti MR, Hasa D, Voinovich D, Gigli L, Demitri N, Geremia S, Keiser J, Cerreia Vioglio P, Albertini B.Eur J Pharm Biopharm. 2018 Jun;127:19-28. doi: 10.1016/j.ejpb.2018.01.018. Epub 2018 Jan 31.PMID: 29409939
3.Zanolla D, Hasa D, Arhangelskis M, Schneider-Rauber G, Chierotti MR, Keiser J, Voinovich D, Jones W, Perissutti B.Pharmaceutics. 2020 Mar 23;12(3):289. doi: 10.3390/pharmaceutics12030289.PMID: 32210129
4.Salas-Zúñiga R, Mondragón-Vásquez K, Alcalá-Alcalá S, Lima E, Höpfl H, Herrera-Ruiz D, Morales-Rojas H.Mol Pharm. 2022 Feb 7;19(2):414-431. doi: 10.1021/acs.molpharmaceut.1c00606. Epub 2021 Dec 30.
PMID: 34967632
5.Wen X, Deng Z, Xu Y, Yan G, Deng X, Wu L, Liang Q, Fang F, Feng X, Yu M, He J.Pharmaceutics. 2021 Sep 27;13(10):1567. doi: 10.3390/pharmaceutics13101567.PMID: 34683860
Audited Supplier 
){kind=link}